{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:41Z","timestamp":1793805941689,"version":"4.6.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jocn.2026.112202","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:10:13Z","timestamp":1784563813000},"page":"112202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prognostic utility of tumor grade and IDH-mutation status for immunotherapy response in high grade glioma: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"152","author":[{"given":"Srivats","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mirahmadi","family":"Eraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peace","family":"Odiase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksheen","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Guirguis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umaru","family":"Barrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Z.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.jocn.2026.112202_b0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jocn.2026.112202_b0015","doi-asserted-by":"crossref","unstructured":"Brown NF, Ottaviani D, Tazare J, et al. Survival outcomes and prognostic factors in glioblastoma. Cancers (Basel). Jun 28 2022;14(13)doi:10.3390\/cancers14133161.","DOI":"10.3390\/cancers14133161"},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/nop\/npv016","article-title":"Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis","volume":"3","author":"Dong","year":"2016","journal-title":"Neuro-Oncol Practice"},{"issue":"8","key":"10.1016\/j.jocn.2026.112202_b0025","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol."},{"key":"10.1016\/j.jocn.2026.112202_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.944452","article-title":"Advances in immunotherapy for glioblastoma multiforme","volume":"13","author":"Mahmoud","year":"2022","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.jocn.2026.112202_b0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00401-017-1690-1","article-title":"Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT","volume":"133","author":"Pekmezci","year":"2017","journal-title":"Acta Neuropathologica."},{"issue":"8","key":"10.1016\/j.jocn.2026.112202_b0040","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"11","key":"10.1016\/j.jocn.2026.112202_b0045","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.jocn.2026.112202_b0050","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaneurol.2014.1205","article-title":"IDH mutation in glioma: new insights and promises for the future","volume":"71","author":"Turkalp","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jocn.2026.112202_b0055","doi-asserted-by":"crossref","unstructured":"Tiwari A, Alcover K, Carpenter E, et al. Utility of cell-based vaccines as cancer therapy: systematic review and meta-analysis. Hum Vaccin Immunother. Dec 31 2024;20(1):2323256. doi:10.1080\/21645515.2024.2323256.","DOI":"10.1080\/21645515.2024.2323256"},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jocn.2026.112202_b0070","unstructured":"R: A language and environment for statistical computing. R Foundation; 2021."},{"key":"10.1016\/j.jocn.2026.112202_b0075","doi-asserted-by":"crossref","unstructured":"Fekete JT, Gy\u0151rffy B. MetaAnalysisOnline.com: an online tool for the rapid meta-analysis of clinical and epidemiological studies. J Med Internet Res. Jan 18 2025;doi:10.2196\/64016.","DOI":"10.2196\/64016"},{"issue":"7854","key":"10.1016\/j.jocn.2026.112202_b0080","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature."},{"key":"10.1016\/j.jocn.2026.112202_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114034","article-title":"REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas","volume":"202","author":"Picca","year":"2024","journal-title":"Eur J Cancer."},{"issue":"4","key":"10.1016\/j.jocn.2026.112202_b0090","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pbc.22319","article-title":"Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours","volume":"54","author":"Ardon","year":"2010","journal-title":"Pediatr Blood Cancer."},{"issue":"4","key":"10.1016\/j.jocn.2026.112202_b0095","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3171\/2011.12.JNS111255","article-title":"Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma","volume":"116","author":"Chiba","year":"2012","journal-title":"J Neurosurg."},{"issue":"6","key":"10.1016\/j.jocn.2026.112202_b0100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/14653249.2012.666633","article-title":"Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor \u03b12 chain in recurrent malignant glioma patients with HLA-A*24\/A*02 allele","volume":"14","author":"Iwami","year":"2012","journal-title":"Cytotherapy."},{"issue":"11","key":"10.1016\/j.jocn.2026.112202_b0105","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.21873\/anticanres.14669","article-title":"Alpha-type-1 polarized dendritic cell-based vaccination in newly diagnosed high-grade glioma: a phase II clinical trial","volume":"40","author":"Mitsuya","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jocn.2026.112202_b0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jocn.2020.03.006","article-title":"A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma","volume":"74","author":"Rudnick","year":"2020","journal-title":"J Clin Neurosci."},{"issue":"2","key":"10.1016\/j.jocn.2026.112202_b0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00262-018-2274-1","article-title":"A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma","volume":"68","author":"Tsuboi","year":"2019","journal-title":"Cancer Immunol Immunother."},{"issue":"7","key":"10.1016\/j.jocn.2026.112202_b0120","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/sj.bjc.6601268","article-title":"Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I\/II trial","volume":"89","author":"Yamanaka","year":"2003","journal-title":"Br J Cancer."},{"issue":"11","key":"10.1016\/j.jocn.2026.112202_b0125","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-05-0120","article-title":"Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I\/II trial","volume":"11","author":"Yamanaka","year":"2005","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.jocn.2026.112202_b0130","doi-asserted-by":"crossref","unstructured":"Yuce Sari S, Aktas BY, Kertmen N, et al. Does combined fractionated stereotactic radiotherapy and immunotherapy change the outcome of recurrent high-grade gliomas? Cureus. Jun 2021;13(6):e15852. doi:10.7759\/cureus.15852.","DOI":"10.7759\/cureus.15852"},{"issue":"5","key":"10.1016\/j.jocn.2026.112202_b0135","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting","volume":"10","author":"Chiocca","year":"2004","journal-title":"Mol Ther."},{"issue":"3","key":"10.1016\/j.jocn.2026.112202_b0140","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.mt.6300403","article-title":"A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas","volume":"16","author":"Forsyth","year":"2008","journal-title":"Mol Ther."},{"issue":"3b","key":"10.1016\/j.jocn.2026.112202_b0145","first-page":"1861","article-title":"Autologous natural killer cell therapy for human recurrent malignant glioma","volume":"24","author":"Ishikawa","year":"2004","journal-title":"Anticancer Res. May-Jun"},{"issue":"6","key":"10.1016\/j.jocn.2026.112202_b0150","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000421-200212000-00001","article-title":"Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment","volume":"25","author":"Emrich","year":"2002","journal-title":"Am J Clin Oncol."},{"issue":"4","key":"10.1016\/j.jocn.2026.112202_b0155","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s002590050397","article-title":"Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin","volume":"26","author":"Paganelli","year":"1999","journal-title":"Eur J Nucl Med."},{"issue":"5","key":"10.1016\/j.jocn.2026.112202_b0160","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2002.20.5.1389","article-title":"Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas","volume":"20","author":"Reardon","year":"2002","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2005.03.4082","article-title":"Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results","volume":"24","author":"Reardon","year":"2006","journal-title":"J Clin Oncol."},{"issue":"2","key":"10.1016\/j.jocn.2026.112202_b0170","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1215\/15228517-2007-053","article-title":"A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost","volume":"10","author":"Reardon","year":"2008","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.jocn.2026.112202_b0175","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3171\/2014.12.JNS142168","article-title":"Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy","volume":"123","author":"Reulen","year":"2015","journal-title":"J Neurosurg."},{"issue":"3","key":"10.1016\/j.jocn.2026.112202_b0180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/hyb.2006.25.125","article-title":"Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors","volume":"25","author":"Wygoda","year":"2006","journal-title":"Hybridoma (Larchmt)."},{"issue":"4","key":"10.1016\/j.jocn.2026.112202_b0185","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/neuonc\/noy202","article-title":"Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma","volume":"21","author":"Kieran","year":"2019","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0190","article-title":"Adjuvant temozolomide chemotherapy with or without interferon alfa among patients with newly diagnosed high-grade gliomas: a randomized clinical trial","volume":"6","author":"Guo","year":"2023","journal-title":"JAMA Netw Open. Jan 3"},{"key":"10.1016\/j.jocn.2026.112202_b0195","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3389\/fimmu.2018.00727","article-title":"Predictors of response to autologous dendritic cell therapy in glioblastoma multiforme","volume":"9","author":"Jan","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.jocn.2026.112202_b0200","doi-asserted-by":"crossref","unstructured":"Lepski G, Bergami-Santos PC, Pinho MP, et al. Adjuvant vaccination with allogenic dendritic cells significantly prolongs overall survival in high-grade gliomas: results of a phase II Trial. Cancers (Basel). Feb 15 2023;15(4)doi:10.3390\/cancers15041239.","DOI":"10.3390\/cancers15041239"},{"issue":"3","key":"10.1016\/j.jocn.2026.112202_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247293","article-title":"Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I\/IIa trial","volume":"16","author":"Lim","year":"2021","journal-title":"PLoS One."},{"issue":"2","key":"10.1016\/j.jocn.2026.112202_b0210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1016\/j.jocn.2026.112202_b0215","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"7985","key":"10.1016\/j.jocn.2026.112202_b0220","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature."},{"issue":"8","key":"10.1016\/j.jocn.2026.112202_b0225","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jocn.2026.112202_b0230","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","article-title":"Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies","volume":"28","author":"van Putten","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"4","key":"10.1016\/j.jocn.2026.112202_b0235","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med."},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0240","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer."},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41746-023-00948-y","article-title":"Prognosis individualized: survival predictions for WHO grade II and III gliomas with a machine learning-based web application","volume":"6","author":"Karabacak","year":"2023","journal-title":"npj Digital Med"},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0250","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41598-017-19014-1","article-title":"Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification","volume":"8","author":"Im","year":"2018","journal-title":"Sci Rep."},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0255","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/cco-22-120","article-title":"2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review","volume":"12","author":"Thomas","year":"2023","journal-title":"Chin Clin Oncol."},{"issue":"7","key":"10.1016\/j.jocn.2026.112202_b0260","first-page":"e1788","article-title":"Concurrent immunotherapy and re-irradiation utilizing stereotactic body radiotherapy for recurrent high-grade gliomas","volume":"6","author":"Mahase","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0265","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00262-021-02954-z","article-title":"Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy","volume":"71","author":"Yokota","year":"2022","journal-title":"Cancer Immunol Immunother."},{"issue":"2","key":"10.1016\/j.jocn.2026.112202_b0270","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CJI.0b013e3182811ae4","article-title":"Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients","volume":"36","author":"Prins","year":"2013","journal-title":"J Immunother."},{"issue":"3","key":"10.1016\/j.jocn.2026.112202_b0275","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11060-024-04813-0","article-title":"Advancements and challenges: immunotherapy therapy in high-grade glioma- a meta-analysis of randomized clinical trials","volume":"170","author":"Palavani","year":"2024","journal-title":"J Neurooncol."},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0280","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/noac207","article-title":"Isocitrate dehydrogenase (IDH) mutant gliomas: a society for neuro-oncology (SNO) consensus review on diagnosis, management, and future directions","volume":"25","author":"Miller","year":"2023","journal-title":"Neuro-Oncol"},{"issue":"4","key":"10.1016\/j.jocn.2026.112202_b0285","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1172\/JCI90644","article-title":"Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas","volume":"127","author":"Kohanbash","year":"2017","journal-title":"J Clin Invest."},{"issue":"2","key":"10.1016\/j.jocn.2026.112202_b0290","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","article-title":"Biological role and therapeutic potential of IDH mutations in cancer","volume":"34","author":"Waitkus","year":"2018","journal-title":"Cancer Cell."},{"issue":"29","key":"10.1016\/j.jocn.2026.112202_b0295","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1016\/j.jocn.2026.112202_b0300","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","journal-title":"Nat Med."},{"issue":"1","key":"10.1016\/j.jocn.2026.112202_b0305","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41698-024-00646-2","article-title":"Treatment of IDH-mutant glioma in the INDIGO era","volume":"8","author":"Lin","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"5","key":"10.1016\/j.jocn.2026.112202_b0310","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/noz016","article-title":"Accelerated progression of IDH mutant glioma after first recurrence","volume":"21","author":"Miller","year":"2019","journal-title":"Neuro Oncol."},{"issue":"10","key":"10.1016\/j.jocn.2026.112202_b0315","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1541-7786.MCR-16-0141","article-title":"Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis","volume":"14","author":"Johannessen","year":"2016","journal-title":"Mol Cancer Res."}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758682600353X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758682600353X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:28:37Z","timestamp":1793802517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096758682600353X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":63,"alternative-id":["S096758682600353X"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112202","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic utility of tumor grade and IDH-mutation status for immunotherapy response in high grade glioma: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112202"}}